Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 + Apatinib in Advanced HCC
NCT04014101Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2019
- Primary completion
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04014101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014101.